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Metabolomics guided pathway analysis
reveals link between cancer metastasis,
cholesterol sulfate, and phospholipids
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Nicholas J. W. Rattray2, Zahra Rattray8, Benedikt Warth1, Melissa Ritland4,9, Linh T. Hoang1, Celine Loriot4,
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Abstract
Background: Cancer cells that enter the metastatic cascade require traits that allow them to survive within the
circulation and colonize distant organ sites. As disseminating cancer cells adapt to their changing
microenvironments, they also modify their metabolism and metabolite production.
Methods: A mouse xenograft model of spontaneous tumor metastasis was used to determine the metabolic
rewiring that occurs between primary cancers and their metastases. An “autonomous” mass spectrometry-based
untargeted metabolomic workflow with integrative metabolic pathway analysis revealed a number of differentially
regulated metabolites in primary mammary fat pad (MFP) tumors compared to microdissected paired lung
metastases. The study was further extended to analyze metabolites in paired normal tissues which determined the
potential influence of metabolites from the microenvironment.
Results: Metabolomic analysis revealed that multiple metabolites were increased in metastases, including
cholesterol sulfate and phospholipids (phosphatidylglycerols and phosphatidylethanolamine). Metabolite analysis of
normal lung tissue in the mouse model also revealed increased levels of these metabolites compared to tissues
from normal MFP and primary MFP tumors, indicating potential extracellular uptake by cancer cells in lung
metastases. These results indicate a potential functional importance of cholesterol sulfate and phospholipids in
propagating metastasis. In addition, metabolites involved in DNA/RNA synthesis and the TCA cycle were decreased
in lung metastases compared to primary MFP tumors.
Conclusions: Using an integrated metabolomic workflow, this study identified a link between cholesterol sulfate
and phospholipids, metabolic characteristics of the metastatic niche, and the capacity of tumor cells to colonize
distant sites.
Keywords: Cancer, Cholesterol sulfate, Phospholipids, Autonomous metabolomics, Mummichog, Metastasis, XCMS
* Correspondence: caroline.johnson@yale.edu; brunie@scripps.edu;
siuzdak@scripps.edu
†Equal contributors
1Scripps Center for Metabolomics, The Scripps Research Institute, La Jolla, CA,
USA
4Department of Molecular and Experimental Medicine, The Scripps Research
Institute, La Jolla, CA, USA
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Johnson et al. Cancer & Metabolism  (2017) 5:9 
DOI 10.1186/s40170-017-0171-2
Background
The biology of metastatic cancer is complex, and cells that
enter the metastatic cascade encounter a multitude of
challenges. The fraction of malignant cells that are shed
from the primary tumor require traits that allow them to
survive in circulation and colonize distant organs [1].
Once seeded, the cells must adapt to the new pool of
extracellular metabolites available and survive immune
surveillance. To do this, cancer cells reprogram their
microenvironment to assist tumor growth. Thus, the me-
tabolism, growth, and survival of the metastatic cells are
likely dependent on the attributes of the new site.
As cancer cells proliferate, they require energy to
synthesize macromolecules, support cell growth, and main-
tain redox homeostasis [2, 3]. Sources of energy can be con-
trolled by the expression of metabolic enzymes such as
hexokinase which converts glucose to glucose-6-phosphate
in the glycolysis pathway, as seen in many cancers, including
glioblastoma multiforme [4]. However, cancer cells can also
utilize transporters to help produce and import metabolites
from the microenvironment. A recent study revealed that
metastatic cells release an enzyme into the extracellular
space catalyzing the phosphorylation of creatine. Phospho-
creatine is then imported into disseminated cancer cells to
generate adenosine triphosphate (ATP), fueling metastatic
survival [5]. Moreover, stromal-epithelial metabolic coupling
has been described for symbiotic nutrient sharing in cancer.
A recent report revealed that adipocytes in the omentum
provide fatty acids for primary ovarian cancers promoting
rapid tumor growth and metastasis [6]. Metabolites can also
be directly involved in increasing cancer cell growth, for ex-
ample, succinate and fumarate are known to inhibit prolyl
hydroxylase enzymes producing a pseudo-hypoxic state,
driving glycolysis, and tumor proliferation [7]. Therefore,
understanding the metabolism of cancer cells in a primary
tumor versus those that have metastasized to a secondary
organ site can reveal metabolic adaptions of a disseminating
cancer cell.
A recently developed autonomous metabolomic workflow
was implemented with integrative metabolic pathway ana-
lysis to identify metabolites and guide further biological in-
vestigation [8]. A MDA-MB-435 xenograft model was used
to generate mammary fat pad (MFP) tumors in the mouse
and spontaneous metastases to the lung, to test the hypoth-
esis that metastatic cells undergo a metabolic adaption to
survive the new microenvironment [9]. These cancer tissues
were subjected to comprehensive metabolomics and pathway
analyses, which revealed a number of metabolic dependen-
cies for cancer cells that resided in these tissues.
Methods
The aims of this study were to assess the metabolic dif-
ferences between primary tumors and spontaneous me-
tastases. To carry out a comprehensive analysis of
metabolites in tissues, we used an autonomous mass
spectrometry-based metabolomic workflow on primary
tumor and metastasis tissue extracts [8].
Cell culture
MDA-MB-435 cells were grown in EMEM supplemented
with nonessential amino acids, vitamins, 2 mM L-glutam-
ine, 1 mM pyruvate, and 10% fetal bovine serum.
Animal treatment and sample collection
Six- to eight-week-old female C.B-17/SCID mice were
injected with F-luc-tagged cancer cells: 2.5 × 105 (30 μl)
MDA-MB-435 cells into the fourth mammary fat pad.
Primary tumors were removed surgically when they
reached 300 mm3 in size (approximately 4 weeks post-
injection), the endpoint. Mice were then examined
weekly (IVIS 200, Xenogen) by non-invasive biolumines-
cence imaging, 10 min after i.p. injection of D-luciferin
(100 mg/kg) to assess the presence of lung metastasis.
Animals were sacrificed 24 h after bioluminescence sig-
nal on the chest reached 1 × 107 photons/s/cm2. In
order to eliminate any artefacts that could occur with
the enzymatic procedure, i.p. injection of D-luciferin was
not used for the final dissection. Animal work complied
with the National Institutes of Health and institutional
guidelines (TSRI is AAALAC accredited).
Tissue sample extraction
Three sections were taken from different regions of
mammary fat pad tumors (core, middle, edges) with a
combined approximate weight of 15 mg. The tissues
were added to high recovery glass vials (Agilent Tech-
nologies, Santa Clara, CA) on dry ice. Lung metastases
were first assessed by bioluminescence imaging, as de-
scribed above, to guide the microdissection under the
microscope. The microdissected metastasis was then
pooled for each mouse, then similarly placed in vials on
dry ice. Each sample was homogenized in 400 μl metha-
nol/water (4:1) and 1 mm glass beads (BioSpec Products,
Bartlesville, OK) for 30 s at 3500 rpm. The homogenate
was added to glass vials, sonicated for 10 min at room
temperature, and stored at − 20 °C overnight. Samples
were then centrifuged at 13,000 rpm for 15 min and the
supernatant transferred to a new 1.5-ml centrifuge tube.
The pellet was resuspended in 600 μl ice cold acetone,
vortexed for 10 s, and sonicated for 10 min at room
temp. The pellet samples were stored at − 20 °C for 1 h
followed by centrifugation (13,000 rpm for 15 min). The
supernatant was pooled with the supernatant collected
earlier and dried down in a Speedvac for 4 h. The pellet
was used for protein quantification by microBCA
(Thermo Fisher Scientific, Waltham, MA).
Samples were resuspended in acetonitrile/water/iso-
propanol (50/40/10 v/v) according to the protein
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concentration; the lowest concentration was resus-
pended in 40 μl and the other samples adjusted accord-
ingly. Each sample was then sonicated for 10 min,
centrifuged at 13,000 rpm for 15 min, and the superna-
tants transferred to glass HPLC vials for LC/MS analysis.
Untargeted metabolomic analysis
Samples were randomized and analyzed by high-
performance liquid chromatography-electrospray
ionization quadrupole time-of-flight mass spectrometry
(HPLC-ESI-QTOFMS). A pooled sample containing
10 μl of each individual sample was injected (5 μl) every
five injections for quality control. In addition, a water-
based wash and blank were run after each sample. The
samples were analyzed by hydrophilic interaction liquid
chromatography (HILIC) analysis as previously de-
scribed [10] using an Agilent 6550 ion funnel QTOF in
ESI negative mode. HILIC analysis was used as we were
aiming to identify the polar metabolites which have been
previously shown to have roles in cancer metabolism
[11]. Each sample (5 μl) was injected onto a Luna Ami-
nopropyl column, 3 μm, 150 mm × 1.0 mm I.D. (Phe-
nomenex), the mobile phase was composed of A =
20 mM ammonium acetate and 40 mM ammonium hy-
droxide in 95% water and B = 95% acetonitrile. The lin-
ear gradient elution from 100% B (0–5 min) to 100% A
over 50 mins, held at 100% A for 5 min, and a 10-min
post-run at a flow rate of 50 μl/min.
ESI source conditions were set as follows: gas
temperature 200 °C, drying gas 11 l/min, nebulizer
15 psi, fragmentor 365 V, sheath gas temperature 300 °
C, sheath gas flow 9 l/min, nozzle voltage 500 V, and ca-
pillary voltage − 2500 V. The instrument was set to ac-
quire over the m/z range 60–1000 with a MS acquisition
rate of 1.67 spectra/s. The data were processed using
XCMS Online [12]. Paired parametric tests were per-
formed, with a p value < 0.05 having statistical signifi-
cance. The q value was also assessed to eliminate false
positive results. Features were compiled in a feature list
table and as an interactive cloud plot, containing inte-
grated intensities (extracted ion chromatographic peak
areas), observed fold changes across the two sample
groups, and statistical significance for each sample. Ten-
tative metabolic pathways were identified using mummi-
chog version 0.10.3, available as part of the XCMS
Online program. An autonomous metabolomic workflow
was also carried out for each sample by HILIC-MS in
ESI negative mode to obtain an automatic list of metab-
olite identifications post-run. These identifications are
based on precursor mass and fragment ions [8]. Acquisi-
tion was as follows: MS mode acquisition rate 2.86 spec-
tra/s; MS/MS mode acquisition rate 13.33 spectra/s at
20 eV with a narrow isolation width (1.3 Da); 10 max
precursors per cycle, with active exclusion after 4
spectra, released after 0.15 min; and a threshold of 200
counts. Two contaminant ions with m/z’s 172.9297 and
248.9762 were excluded throughout the whole run. Me-
tabolite identifications were further confirmed by com-
paring retention time and tandem MS to standard
compounds. For targeted identification of selected pre-
cursors, the default isolation width was set as narrow
(1.3 Da), with a MS acquisition rate at 2.87 spectra/s
and MS/MS acquisition at 2.87 spectra/s. The collision
energy was set to 20 and 40 eV on separate runs. An
overview of the workflow can be seen in Fig. 1.
Results
Metabolomic analysis reveals increased lipid species in
metastasis
An untargeted metabolomic approach was used to iden-
tify metabolites in extracts of primary tumors and their
spontaneous microdissected lung metastases (n = 4/
group). Of note, animals were euthanized when there
was a bioluminescence signal of 1 × 107 photons/s/cm2
for the lung metastasis. Paired analyses revealed a total
of 10,329 aligned metabolic features. Filtering to remove
isotopes and noise prioritized 110 features that were sig-
nificantly different in abundance between the two groups
of samples (p value < 0.01, q value < 0.1, fold change > 2,
intensity > 10,000, paired t test) (XCMS Online Job ID
#1060717). In order to identify the features, an autono-
mous workflow was used which acquired both quantita-
tive MS and qualitative MS/MS data. The data were
simultaneously matched to MS/MS fragmentation pat-
terns on the METLIN database [8]. Using this function,
it was possible to identify uridine monophosphate
(UMP), guanosine monophosphate (GMP), glutamine,
and cholesterol sulfate (Fig. 2). In order to increase the
identification of metabolite features, additional targeted
MS/MS was carried out on precursor ions from the pri-
oritized list, confirming the presence of citrate/isocitrate,
N6-succino adenosine, cytidine monophosphate (CMP),
16:0 Lyso phosphoethanolamine (PE), and 16:0 phospha-
tidylglycerol (PG). These metabolites were further con-
firmed by comparison to authentic standards. Table 1
displays these metabolites, their significance, and p
values in relation to their increased abundance in pri-
mary tumors or lung metastases. In order to expand on
the analysis and provide biological meaning to the me-
tabolites, we used the network mapping tool mummi-
chog to assess interconnectivity of metabolites in
biological pathways [13]. This software looks at patterns
of related putatively identified metabolites (based on
their m/z only) to lead further metabolite identification;
it is integrated as part of the XCMS Online platform
[12]. The top metabolite predictions made by mummi-
chog were glutamine, CMP, GMP, UMP, citrate/isoci-
trate, and adenosine monophosphate (AMP). AMP was
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further confirmed against a standard. As the pathway
analyses indicated an involvement of nucleotide
(p = 0.00139), glutamate (p = 0.00336), and phosphocho-
line (p = 0.01843) metabolism, these pathways were in-
vestigated further and revealed significant differences to
other metabolites housed in these pathways: uridine 5′-
diphospho (UDP)-glucuronate, N-acetyl-L-glutamate,
16:0 Lyso PG (DDPG), and 16:0–18:1 PG (POPG)
(Fig. 2). The LipidMaps database was used to further pu-
tatively identify DDPG, and POPG by MS/MS fragmen-
tation patterns, and was confirmed by comparison to
standards. Thus, the metabolites upregulated in metasta-
ses included phospholipids and cholesterol sulfate, and
those upregulated in the primary tumor were involved
primarily in glutamate metabolism and nucleotide syn-
thesis. Additional file 1: Figure S1 shows the distribu-
tions for each of the metabolites.
The cancer cell microenvironment as a source of nutrients
In order to assess the possibility of metabolite uptake
from the microenvironment, samples were analyzed
from normal MFP and lung tissues and compared to
MFP tumors and lung metastasis (n = 5/group). The
XCMS Online platform was used to perform multigroup
analysis by ANOVA (Job ID: 1095497) revealing the dis-
tributions of the metabolites in the tissues [14]. Figure 3
shows a cloud plot of all the statistically significant fil-
tered features. It can be seen that a number of metabo-
lites that were increased in the metastasis or primary
tumors were at similar abundances in their normal sur-
rounding tissues. These metabolites include glutamine,
cholesterol sulfate, and phospholipid compounds, indi-
cating that the microenvironment could be a source of
metabolites for cancer cells (Figs. 3 and 4). There were
also a number of metabolites that were only significantly
upregulated in tumor tissues and not in normal tissues:
citrate/isocitrate, UDP-glucuronate, and mononucleo-
tides Figs. 3 and 4).
Discussion
The metabolism of a cancer cell depends on both its gen-
etic reprogramming during malignant transformation and
tumor progression, as well as on its interactions with the
tumor microenvironment. In this study, we used an au-
tonomous metabolomic workflow to uncover the meta-
bolic differences between cancer cells in a primary tumor,
and those that have metastasized to a distant organ. Paired
analysis of primary MFP tumors and lung metastases in a
xenograft model revealed a number of significantly altered
metabolites between the tissues. Notably, cholesterol sul-
fate was highly upregulated in spontaneous pulmonary
metastases compared to their paired primary tumors and
thus raised interest for further investigation due to its
previously implicated roles in cancer invasion and cell sig-
naling. Cholesterol sulfate is a metabolic product of chol-
esterol and, along with phospholipids and ceramides, is
integral to maintaining the cellular plasma membrane and
determines its elasticity. This metabolite has known sig-
naling functions and can modify the activity of serine pro-
teinases of the coagulation cascade [15, 16]. Thus, it can
potentially promote platelet interaction with circulating
cells including disseminating tumor cells within the blood-
stream [15, 16]. Cholesterol sulfate can also accelerate the
proteolytic activity of matrix metalloproteinase-7 towards
selective substrates in the extracellular matrix, thus poten-
tially aiding in metastasis [17], and can regulate protein
kinase C, which is involved in cellular differentiation and
carcinogenesis [18].
Fig. 1 Overview of metabolomic workflow. Untargeted metabolomic analysis was carried out on tissue extracts from a mouse model of
metastasis. Autonomous metabolomic and pathway analysis of paired tissues (primary tumor versus metastasis) revealed correlated metabolic
pathway changes, in particular the increased production of cholesterol sulfate in metastasis
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In our study, comparison of normal and tumor tissues
also revealed that cholesterol sulfate was higher in both
normal lung tissue extracts and lung metastases com-
pared to MFP. The lung metastases were microdissected
and validated to contain only minimal traces of normal
lung tissue. Therefore, the presence of this metabolite in
pulmonary lesions could have arisen by uptake from the
extracellular environment as well as by cancer cell pro-
duction. For the latter hypothesis, it is possible that a
subset of cells within the primary tumor have increased
expression of cholesterol sulfotransferase, facilitating the
production of cholesterol sulfate and thereby supporting
hematogenous dissemination of metastatic cancer cells
to the lung.
In addition to the roles of cholesterol sulfate itself, the
enzyme sulfotransferase (SULT)2B1b which has a high
affinity for cholesterol sulfonation has also been linked
to carcinogenesis [19]. Recent studies in mice have
shown that prostate cancer cells with RNAi-mediated
knockdown of SULT2B1b decrease cell growth and in-
duce cell death [20]. In addition, SULT2B1b promoted
proliferation of hepatocellular carcinoma cells [21],
Fig. 2 Paired untargeted metabolomics analysis of primary mammary fat pad tumors compared to lung metastasis (n = 4). Upper panel,
autonomous metabolomics aids in the identification of metabolites by automated tandem MS matching to the METLIN database; the panels
show experimental and reference tandem MS comparisons for glutamine, cholesterol sulfate, uridine monophosphate and guanosine
monophosphate at a collision energy of 20 eV. Lower panel, mummichog pathway analysis integrated with XCMS Online software, reveals
pathways that are putatively correlated to differences between primary and metastatic cancer cells
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decreased migration of a metastatic non-small cell lung
cancer cell line [22], and promoted angiogenesis in gas-
tric cancer [23] and cell growth and invasion in colorec-
tal cancer [24]. Studies also show that patients whose
tumors express higher levels of SULT2B1b have a worse
prognosis [22–25]. There is strong evidence that indi-
cates a role for both SULT2B1b and cholesterol sulfate
in cancer; our hypothesis is that the target organ uses
cholesterol sulfate to facilitate seeding of metastatic
cancer cells.
In addition to changes in cholesterol sulfate, phospho-
lipids were also highly upregulated in metastases. They
were also similarly elevated in normal lung tissues and
lung metastases. Phospholipids have been previously as-
sociated with cancer, with proposed mechanisms in pro-
tein trafficking, promoting the onset and progression of
Table 1 List of metabolites significantly changed in metastasis tissues (n = 4) compared to primary tumor tissues (n = 4), paired
Welch’s t test
Metabolite name Mass-to-charge ratio
[M-H]−
Fold change Retention time (min) Direction of change
in metastasis
p value
Cholesterol sulfate 465.3050 5.7 15.59 ↑ 4.00E−04
16:0 Lyso phosphatidylethanolamine 452.2771 3.0 16.67 ↑ 1.86E−03
DPPG (16:0 phosphatidylglycerol) 721.5012 15.2 17.11 ↑ 2.80E−03
POPG (16:0/18:1 phosphatidylglycerol) 747.5185 2.5 17.03 ↑ 1.41E−02
16:0 Lyso phosphatidylglycerol 483.2719 14.0 18.66 ↑ 1.68E−02
Cytidine monophosphate 322.0443 4.3 36.70 ↓ 9.20E−04
Citrate/isocitrate 191.0202 2.8 42.79 ↓ 1.20E−03
Guanosine monophosphate 362.0505 2.2 39.84 ↓ 1.24E−03
Uridine monophosphate 323.0286 3.8 36.96 ↓ 2.40E−03
N6-succinyl adenosine 382.0999 7.0 36.42 ↓ 4.44E−03
Glutamine 145.0621 1.8 21.63 ↓ 6.14E−03
N-acetyl-L-glutamate 188.0565 6.5 34.66 ↓ 4.32E−02
Adenosine monophosphate 346.0560 2.0 37.23 ↓ 4.92E−02
Uridine 5′-diphosphoglucuronate 579.0262 2.1 42.95 ↓ 4.99E−02
Fig. 3 Multigroup analysis by XCMS Online. Cloud plot represents significantly altered metabolites, and box-and-whisker plots detail the relative
abundance of metabolites in all four tissue types (ANOVA with Bonferroni correction, n = 5/group, p < 0.015)
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the disease [26]. They have also been associated with
metastatic cancer cells [27]. It has been previously dem-
onstrated that fatty acids are synthesized de novo for
phospholipid and subsequent cell membrane synthesis.
However, a recent study showed that proliferating cells
scavenge highly abundant fatty acids from the extracellu-
lar environment for phospholipid synthesis, in contrast
to cells that are surrounded by low concentrations of
fatty acids and carry out de novo synthesis [28]. Con-
versely, cancer cells can scavenge unsaturated fatty acids
from lysophospholipids [29]. In addition, studies have
shown that cancer cells use macropinocytosis to internalize
extracellular proteins which then undergo proteolytic deg-
radation, yielding amino acids for growth [30, 31]. Thus, it
is possible that it is more efficient for cancer cells to take
up nutrients from the microenvironment, where they are
in high supply, rather than, or in addition to, utilizing intra-
cellular resources for de novo synthesis [32]. Likewise, in
normal MFP tissues, glutamine was at similar abundance
levels to those found in the primary MFP tumors, indicat-
ing that these cancer cells may also use the microenviron-
ment as a source of energy-rich metabolites. However,
there were a large number of metabolites that were only
increased in the primary tumors and not present in normal
tissue:citrate/isocitrate, AMP, GMP, CMP, UMP, and UDP-
glucuronate indicating that these metabolites are generated
intracellularly by the tumor cells and are either not taken
up from the microenvironment or are potentially products
of other metabolites.
As aforementioned, there were several metabolites in-
volved in DNA/RNA synthesis and the TCA cycle that
were elevated in primary tumors compared to metastases.
This indicates that the metastases have depleted nutrients
available for nucleotide synthesis, including essential co-
factors such as NADPH. De novo lipogenesis, which
similarly requires high levels of NADPH, is shut down to
preserve NADPH for nucleotide synthesis and cancer cell
survival; therefore, cells use alternative methods to scav-
enge nutrients for growth, such as fatty acids from phos-
pholipids [29, 33]. Fatty acids derived from phospholipids
can supply more energy to the cell through mitochon-
drial oxidation than from oxidation of glucose or amino
acids, so are an important nutrient source for the tumor
cell [34]. This hypothesis is further supported by the de-
creased levels of both glutamine and citrate by the metas-
tases; glutamine can undergo reductive carboxylation to
Fig. 4 Distribution of relative abundances for metabolites in tumor and normal tissues. a Metabolites increased in primary tumor only. b Metabolites
increased in normal stroma and tumor. Box-and-whisker plots generated by XCMS Online for a multigroup analysis (ANOVA, n = 5/group, whiskers,
median with minimum-maximum; boxes, interquartile range) (POPG = 16:0/18:1 phosphatidylglycerol)
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citrate for lipid generation [35]. Phospholipid scavenging
has previously been reported for cells that are under hyp-
oxic stress and require additional nutrients for growth
[29]. Cells that have constitutive mTORC1 signaling and
hypoxia also have been shown to have a dependency on
extracellular desaturated fatty acids to support protein
synthesis [36]. Of importance, tumor cells that acquire
lipids through extracellular scavenging are resistant to
stearoyl-CoA desaturase 1 (SCD1) inhibitors [29].
The metabolic changes that occur in cancer cells that
gain metastatic activity have been reported in the litera-
ture, and it is evident that tumor cell metabolic rewiring
is dependent on the organ in which the metastatic cells
are seeded. A recent study showed that breast cancer
cells which metastasize to the liver favor glycolysis, while
those that metastasized to the lung and bone favor oxi-
dative phosphorylation (OXPHOS) [37]. This difference
is likely due to genetic features that underlie specific
cancer subtypes. A study of clinical samples from 15
cancer types in the Cancer Gene Atlas consortium
showed that suppression of OXPHOS genes was a com-
mon feature of metastases when comparing to primary
tumors and correlated with poorer clinical outcome [38].
It also confirmed that metastasis is not only dependent
on genetics but also on the metabolic environment of
the new organ site.
Conclusions
Metabolic reprogramming, recognized as a typical hall-
mark of cancer cell metabolism, is influenced by an
interplay between tumor microenvironment and genetic
complement that has given rise to the developments of a
new generation of therapeutics. Herein, this study re-
ports a model for rapid identification of metabolites in
primary tumors and metastases and has shown that
cholesterol sulfate and phospholipid species are highly
upregulated in metastasis. Our hypothesis is that tumor
cells scavenge fatty acids, as an alternative energy source
concomitant with observed decrease of nucleotides, glu-
tamine, and citrate, indicating a nutrient-depleted meta-
static phenotype associated with tumor aggression.
Future studies will further assess the role of cholesterol
sulfate and phospholipids in fueling metastatic cancer
and the involvement of transporters in mediating the
flow of metabolites between disseminating tumor cells
and their microenvironments.
Additional file
Additional file 1: Figure S1. Distributions of relative abundance for each
confirmed metabolite. Box-and-whisker plots were generated by XCMS Online
(whiskers, median with minimum-maximum; boxes, interquartile range).
(PG phosphatidylglycerol, PE phosphoethanolamine, DPPG 16:0 phosphatidyl-
glycerol, POPG 16:0/18:1 phosphatidylglycerol.) (TIFF 357 kb)
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